



**Dr. Andrew Dahlem, Ph.D.**

Andrew M. Dahlem, Ph.D., was named vice president and chief operating officer for Lilly Research Laboratories in February 2007. He had been vice president of toxicology, drug disposition, pharmacokinetics, and Lilly Research Laboratories in Europe since January 2003 and a member of Lilly's Senior Management Council since 2005.

Dr. Dahlem received a Bachelor of Science degree from The Ohio State University in 1982 and a doctor of philosophy degree in toxicology from the Veterinary College of the University of Illinois at Urbana-Champaign in 1989.

Dahlem began his career at Merrell Dow Pharmaceuticals in Cincinnati, Ohio, and joined Lilly in 1990 as a senior pharmacologist. He became head of biochemical toxicology in 1992 and was named director of drug disposition and biochemical (investigative) toxicology in 1993. He was promoted to executive director for toxicology and drug disposition in 1998, and he assumed responsibility for leadership of strategy and operations of LRL in Europe in 1999 and for discovery operations in 2000. In December 2001 he was promoted to Vice President in the Toxicology Division.

Dr. Dahlem serves as adjunct professor of toxicology in the College of Veterinary Medicine at Purdue University, the University of Illinois at Urbana-Champaign, and at The Ohio State University. He is also a member of The Ohio State University College of Pharmacy Corporate Council.

Dr. Dahlem is past Chair of the PhRMA Preclinical Safety Leadership Committee (DruSafe) and has held leadership roles in several PhRMA subcommittees. Dr. Dahlem serves on the Board of Directors for Indigo Biosystems, Inc., the YourEncore Board of Advisors, and is a member of the Indiana State Museum Foundation Board.

Dr. Dahlem was a recipient of the first LRL President's Award for Diversity in 2007 and serves as executive sponsor of the Women in Lilly Discovery (WILD) group dedicated to the development, advancement, and retention of outstanding Lilly scientists.